Periostin/OSF-2 Antibody (POSTN/8165R) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-24006H
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunohistochemistry-Paraffin
Label
HRP
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # POSTN/8165R
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Periostin/OSF-2 Antibody (POSTN/8165R) [HRP]
Immunogen
Recombinant fragment (around aa193-326) of human Periostin/OSF-2 protein (exact sequence is proprietary)
Localization
Secreted. Extracellular space. Extracellular matrix.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Applications for Periostin/OSF-2 Antibody (POSTN/8165R) [HRP]
Application
Recommended Usage
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Periostin/OSF-2
Long Name
Osteoblast Specific Factor 2
Alternate Names
Fasciclin I-like, OSF-2, OSF2, POSTN, TRIF52
Gene Symbol
POSTN
Additional Periostin/OSF-2 Products
Product Documents for Periostin/OSF-2 Antibody (POSTN/8165R) [HRP]
Product Specific Notices for Periostin/OSF-2 Antibody (POSTN/8165R) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...